Roche launches 4‑in‑1 donor assay
What happened
Roche introduced the cobas MPX‑E, a single assay that detects HIV, HCV, HBV and HEV to improve blood‑donor screening efficiency and safety in labs. Consolidated donor testing could simplify screening workflows but may also shift lab‑validation and supplier‑qualification responsibilities across manufacturing and safety teams. (x.com)
Why it matters
Roche announced on March 30, 2026 that the cobas MPX‑E assay is now available in countries accepting the European CE mark, giving labs in those markets immediate access to the new test. (roche.com) Roche says the product runs on its fully automated cobas x800 family of systems — platforms the company reports already process more than 10 million tests per month worldwide — and that the assay can be implemented on existing instruments without additional hardware, enabling up to eight hours of “walk‑away” runtime. (roche.com) Technically, Roche describes cobas MPX‑E as a multiplex real‑time PCR test — meaning the chemistry amplifies and reads genetic material from multiple pathogens in parallel, with separate detection channels so each target can be discriminated in the same run — and the assay includes dual‑target detection for HIV‑1 group M, which uses two independent genomic regions to improve sensitivity and reduce the chance of missing infections caused by viral mutations. (roche.com) Roche highlights Hepatitis E (HEV) specifically: the company cites global estimates of about 20 million HEV infections and 70,000 deaths per year and positions the assay as a way to let labs add HEV nucleic‑acid testing (testing for the virus’s RNA) without buying new instruments; HEV screening practices already vary by country and some national bodies have moved toward universal donor screening while others continue formal reviews. (roche.com) (gov.uk) From a regulatory standpoint, Roche’s announcement specifies CE‑mark availability and does not claim US clearance, so use in the United States would require separate FDA authorization or clearance; Roche’s earlier cobas MPX multiplex test previously underwent FDA review and clearance, which demonstrates an existing regulatory precedent for related cobas multiplex donor assays but does not imply MPX‑E has US approval. (roche.com) (fda.gov) Operationally and for compliance teams, adopting a consolidated CE‑marked IVD still triggers formal verification and quality‑management actions at the laboratory and blood‑establishment level: the EU regulatory framework places conformity and post‑market obligations on manufacturers while guidance from EU authorities and Medical Device Coordination Group documents requires laboratories and blood establishments to document local verification, batch performance checks and maintain updated quality systems — items that will require updates to supplier qualification, change‑control and traceability records across procurement, manufacturing and safety functions. (health.ec.europa.eu) (pei.de) (namsa.com) Roche also cited market context for nucleic‑acid testing in donor screening, estimating the global NAT blood‑screening market at roughly 800 million Swiss francs with an expected compound annual growth rate of about 2% from 2024–2029, a figure that procurement and capital‑planning teams can use when modeling cost and supplier consolidation scenarios. (roche.com)
Key numbers
- (x.com) Roche announced on March 30, 2026 that the cobas MPX‑E assay is now available in countries accepting the European CE mark, giving labs in those markets immediate access to the new test.
What happens next
- Consolidated donor testing could simplify screening workflows but may also shift lab‑validation and supplier‑qualification responsibilities across manufacturing and safety teams.
Quick answers
What happened in Roche launches 4‑in‑1 donor assay?
Roche introduced the cobas MPX‑E, a single assay that detects HIV, HCV, HBV and HEV to improve blood‑donor screening efficiency and safety in labs. Consolidated donor testing could simplify screening workflows but may also shift lab‑validation and supplier‑qualification responsibilities across manufacturing and safety teams. (x.com)
Why does Roche launches 4‑in‑1 donor assay matter?
Roche announced on March 30, 2026 that the cobas MPX‑E assay is now available in countries accepting the European CE mark, giving labs in those markets immediate access to the new test. (roche.com) Roche says the product runs on its fully automated cobas x800 family of systems — platforms the company reports already process more than 10 million tests per month worldwide — and that the assay can be implemented on existing instruments without additional hardware, enabling up to eight hours of “walk‑away” runtime. (roche.com) Technically, Roche describes cobas MPX‑E as a multiplex real‑time PCR test — meaning the chemistry amplifies and reads genetic material from multiple pathogens in parallel, with separate detection channels so each target can be discriminated in the same run — and the assay includes dual‑target detection for HIV‑1 group M, which uses two independent genomic regions to improve sensitivity and reduce the chance of missing infections caused by viral mutations. (roche.com) Roche highlights Hepatitis E (HEV) specifically: the company cites global estimates of about 20 million HEV infections and 70,000 deaths per year and positions the assay as a way to let labs add HEV nucleic‑acid testing (testing for the virus’s RNA) without buying new instruments; HEV screening practices already vary by country and some national bodies have moved toward universal donor screening while others continue formal reviews. (roche.com) (gov.uk) From a regulatory standpoint, Roche’s announcement specifies CE‑mark availability and does not claim US clearance, so use in the United States would require separate FDA authorization or clearance; Roche’s earlier cobas MPX multiplex test previously underwent FDA review and clearance, which demonstrates an existing regulatory precedent for related cobas multiplex donor assays but does not imply MPX‑E has US approval. (roche.com) (fda.gov) Operationally and for compliance teams, adopting a consolidated CE‑marked IVD still triggers formal verification and quality‑management actions at the laboratory and blood‑establishment level: the EU regulatory framework places conformity and post‑market obligations on manufacturers while guidance from EU authorities and Medical Device Coordination Group documents requires laboratories and blood establishments to document local verification, batch performance checks and maintain updated quality systems — items that will require updates to supplier qualification, change‑control and traceability records across procurement, manufacturing and safety functions. (health.ec.europa.eu) (pei.de) (namsa.com) Roche also cited market context for nucleic‑acid testing in donor screening, estimating the global NAT blood‑screening market at roughly 800 million Swiss francs with an expected compound annual growth rate of about 2% from 2024–2029, a figure that procurement and capital‑planning teams can use when modeling cost and supplier consolidation scenarios. (roche.com)
